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Since Judah Folkman hypothesized in 1971 that angiogenesis is
required for solid tumor growth, numerous studies have been con-
ducted to unravel the angiogenesis process, analyze its role in pri-
mary tumor growth, metastasis and angiogenic diseases, and to
develop inhibitors of proangiogenic factors. These studies have led in
2004 to the approval of the first antiangiogenic agent (bevacizumab,
a humanized antibody targeting vascular endothelial growth factor)
for the treatment of patients with metastatic colorectal cancer. This
approval launched great expectations for the use of antiangiogenic
therapy for malignant diseases. However, these expectations have
not been met and, as knowledge of blood vessel formation accu-
mulates, many of the original paradigms no longer hold. Therefore,
the regulators and clinical implications of angiogenesis need to be
revisited. In this review, we discuss recently identified angiogenesis
mediators and pathways, new concepts that have emerged over the
past 10 years, tumor resistance and toxicity associated with the use
of currently available antiangiogenic treatment and potentially new
targets and/or approaches for malignant and nonmalignant neovas-
cular diseases.
ABBREVIATIONS: Ang, angiopoietin; BM, basement membrane; BMP, bone morphogenetic protein; CAM, chorioallantoic membrane; CPT, carnitine palmi-
toyltransferase; CRC, colorectal cancer; CSC, cancer stem cell; Dll4, delta-like ligand 4; EC, endothelial cell; ECM, extracellular matrix; EGF, epidermal growth
factor; EGFR, epidermal growth factor receptor; EPC, endothelial progenitor cell; Eph, ephrin receptor; ATS: FA, fatty acid; FGF2, basic fibroblast growth
factor; FOXO1, Forkhead box protein O1; GBM, glioblastomamultiforme; GLUT, glucose transporter; HGF, hepatocyte growth factor; HIF, hypoxia-inducible
factor; IMG, intussusceptivemicrovascular growth;mAb,monoclonal antibody;MAPK,mitogen-activatedprotein kinase;mCRC,metastatic colorectal cancer;
MMP, matrix metalloproteinase; MVD, microvessel density; Nrp, neuropilin; NSCLC, non-small cell lung cancer; PDGF, platelet-derived growth factor; PHD,
prolyl hydroxylase domain; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3; PlGF, placenta growth factor; Robo, roundabout; RTK, recep-
tor tyrosine kinase; SDF-1, stromal cell derived factor-1; Sema, semaphorin; SMA, smoothmuscle cell actin; TAM, tumor-associatedmacrophage; TAN, tumor-
associated neutrophil; TGF, transforming growth factor; TKI, tyrosine kinase inhibitor; VDA, vascular disrupting agent; VE-cadherin, vascular endothelial cad-
herin; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; VHL, von Hippel–Lindau; VM, vasculogenic mimicry
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1 INTRODUCTION
In 2001, we published a review about the regulators and clinical applications of angiogenesis.1 At that time (i) angio-
genesis and vasculogenesis were considered to have distinct functions, the latter restricted to embryogenesis; (ii)
the role of various growth factors, cytokines, proteases, and extracellular matrix (ECM) molecules in the angiogene-
sis process was acknowledged, but mechanistic and inhibitor studies largely focused on vascular endothelial growth
factor (VEGF); (iii) the targeting of genetically stable endothelial cells (ECs) as opposed to genetically unstable and
heterogeneous cancer cells was thought to prevent drug resistance; and (iv) promising mouse xenograft studies
raised high hopes for the anticancer potential of antiangiogenic drugs. Since then, the knowledge about (pathologi-
cal) angiogenesis has increased tremendously: novel insights into tumor vascularization have revealed additional ways
to increase intratumoral blood flow.2 Several new classes of angiogenesis regulators, including proteins involved in
axon guidance3,4 and bone formation5 and microRNAs,6 were found to regulate various aspects of EC biology. EC
metabolism, which only recently received attention, has been put forward as the key determinant of angiogenesis
regulation.7 Antiangiogenic agents failed to provide a consistent and lasting antitumor activity in the clinical set-
ting and were even shown to select for more aggressive tumor cell clones.8 Vessel normalization instead of vessel
regression was found to induce a better antitumor response and to improve the delivery and/or activity of radio- and
chemotherapy.9,10
The aim of this review is to revisit the original paradigms and to highlight insights and concepts in the angio-
genesis field that have emerged over the past years. Rather than presenting an exhaustive study of one particu-
lar topic, we prefer to give an overview of several recent discoveries in the field, in order to offer an update of
current knowledge and thinking about (pathological) blood vessel growth. Accordingly, we mainly refer to papers
that have been published after 2000, but occasionally also to older papers that provided seminal contributions
to the field. For an in-depth analysis regarding specific concepts we refer to specialized reviews throughout the
text.
In particular, this overview focuses on differentmodes of tumor vascularization (Part 2) and novel angiogenesis reg-
ulators and concepts that have been characterized (Part 3). Each type of blood vessel growth displays specific charac-
teristics andmolecular regulators,whichmayunderlie treatment failureusingVEGForVEGFreceptor (VEGFR) target-
ing agents. However, the discovery of novel regulatorymechanisms also provides translational promise. The challenges
of antiangiogenic therapy, as well as potential ways to translate novel insights into improved therapy will be discussed
(Part 4).
2 MECHANISMS THAT CONTRIBUTE TO INCREASED TUMOR
BLOOD SUPPLY
Already in 1971, Folkman hypothesized that solid tumor growth requires angiogenesis, that is, the formation of
new blood vessels from preexisting ones.11 To date, several mechanisms have been shown to contribute to tumor
neovascularization,2 including sprouting angiogenesis,12 intussusceptive growth (nonsprouting angiogenesis, charac-
terized by the division of vessels by transluminal pillar formation),13,14 vascular co-option (hijacking of host capillaries
by the tumor),15 postnatal vasculogenesis (endothelial progenitor cells (EPCs) recruited to the tumor site),16,17 and
vasculogenic mimicry (VM) (blood vessels lined by tumor cells that mimic ECs, Fig. 1).18
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F IGURE 1 Physiological and tumor neovascularization. Physiological neovascularization can occur by sprouting
angiogenesis, the recruitment of bone-marrow-derived EPCs that differentiate into ECs (vasculogenesis), or by ves-
sel splitting/intussusception. Tumors can also co-opt preexisting vessels and tumor vessels can be lined by tumor cells
instead of ECs (vasculogenic mimicry) or by ECs derived from cancer stem cells (CSCs).
2.1 Sprouting angiogenesis
Sprouting angiogenesis was originally defined as amultistep process inwhich activated ECs (e.g., by proangiogenic fac-
tors, such as VEGF)migrate and proliferate to form a new capillary vessel.1,11 This process hasmeanwhile been further
dissected, revealing a tight coordination between migratory tip cells and proliferating stalk cells, and the involvement
of several recently identified regulators (see also chapter 3).
According to the revised model of sprouting angiogenesis,12 activated ECs induce the remodeling of the cell–cell
junctions and the basement membrane (BM), along with detachment of pericytes (i.e., perivascular support cells). This
allows ECs at the leading edge of the sprout to form filopodia and migrate through the ECM in the direction of an
angiogenic stimulus. These migrating tip cells are followed by stalk cells, which proliferate to elongate the new sprout,
forma lumen, and recruit pericytes for stabilization. Tip cells of twomigrating EC fronts connect and fuse (anastomose)
to form a perfused vessel. Upon perfusion, ECs become quiescent phalanx cells, which deposit BM and are covered by
mature pericytes.
2.1.1 Specification of tip and stalk cells
VEGFR2 is expressedonvascular ECs,where it stimulatesECmigration, proliferation, survival, andvascular permeabil-
ity (reviewed in19). However, recent data obtained by several research groups while studying sprouting in the mouse
retina revealed that not all ECs activated by VEGF respond by directed migration and proliferation. In fact, a specifi-
cation between tip and stalk cells exists that is controlled by a crosstalk between VEGF and Notch, a crucial player in
cell–cell communication (reviewed in20).
New sprouts migrate along a chemotactic gradient of VEGF that is produced by the tumor. Consequently VEGF
levels are highest at the leading front of the sprout, where activation of VEGFR2 induces the formation of a migrat-
ing tip cell. In addition, VEGFR2 signaling causes the expression of the Notch ligand delta-like ligand 4 (Dll4). Dll4-
mediated activation of Notch-1 in adjacent ECs suppresses VEGFR2 expression21–23 and increases VEGFR1 (a VEGF
trap) levels.24–26 This renders the cells less responsive to VEGF and promotes the proliferating stalk cell phenotype.
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Thus, an activated tip cell prevents its immediate neighbors from adopting the same phenotype. Moreover, at the
leading edge, ECs compete for the tip cell position. Cellswith higherDll4 levels and lessNotch signalingwill be selected
as tip cells.27
Notch signaling also inhibits VEGFR3 expression, a receptor of VEGF-C. VEGFR3 is highly expressed in endothelial
tip cells in the retina and intersegmental vessels of the zebrafish,28–30 but is downregulated by Notch signaling in the
stalk cells. VEGF-C is less potent thanVEGF in stimulating tip cell activity butmaybecomemore importantwhenVEGF
activity is inhibited.Moreover, VEGF-C/VEGFR3 signaling is required for the stabilization of fusing vascular sprouts.30
Surprisingly, and in contrast to earlier findings, Benedito et al.31 recently demonstrated thatDll4 protein expression
in retinal tip cells is only weakly modulated by VEGFR2 signaling and is even maintained in the absence of VEGFR2.
Moreover, in settings with low Notch activity, Notch was found to upregulate VEGFR3 resulting in strong, ligand-
independent angiogenesis, even in the absence of VEGF/VEGFR2 signaling.32 These context-dependent effects of
Notch may contribute to excessive, nonproductive (poorly perfused and hypoxic) angiogenesis that is seen in tumors
treatedwithNotch inhibitors.33 Clearly, the status ofNotch orVEGFR3 activation in the vasculaturemight be relevant
for patients who do not respond to anti-VEGF treatment.
To identify additional regulators of tip and stalk cell fate, the expression profile of tip and stalk cells has been
compared.34,35 A number of genes are enriched in tip cells, including VEGFR2, platelet-derived growth factor (PDGF)-
B, Dll4,matrixmetalloproteinase (MMP)14, and the chemokine receptorCXCR4.35 However, to date, no single protein
has been identified that can serve asmolecular marker for tip cells. Moreover, tip and stalk cells demonstrate different
types of metabolism (see chapter 3). For their migratory behavior, tip cells require large amounts of ATP, which is gen-
erated primarily by glycolysis. Conversely, stalk cells divide to elongate the newly formed sprout and consequently
require building blocks for rapid macromolecular synthesis (reviewed in36, see further). Thus, the therapeutic impli-
cations of the classification of sprouting ECs into tip and stalk cells stretch beyond the level of angiogenic factors and
their receptors.
2.1.2 Tip cell guidance and vessel anastomosis
Guidance cues are required to direct tip cell migration. This is controlled by several neuronal guidance ligand–receptor
interactions (reviewed in37). Neuropilins (Nrp) are nontyrosine kinase receptors that bind to class 3 semaphorins
(Sema) and to VEGF. Nrp promote tip cell function by enhancing signaling through VEGFR2 and VEGFR3.38–40 Other
important regulators of tip cell guidance are SLIT proteins, which are ligands of the roundabout receptors (Robo), and
Ephrins, which activate Eph tyrosine kinase receptors. In particular, ephrin-B2 increases the formation of tip cells and
filopodia by regulating VEGFR2/VEGFR3 internalization and trafficking.41,42 More information regarding the function
of these recently discovered angiogenesis regulators is provided in chapter 3.
When tip cells of two growing sprouts meet, they have to be connected. This process, called anastomosis, requires
the establishment of new cell–cell junctions. Vascular endothelial (VE)-cadherin is a calcium-dependent adhesion
molecule that controls vascular integrity both in developing and existing vessels.43 However, VE-cadherin is not only
present at endothelial cell–cell contacts but also at the filopodia of the tip cells, suggesting that it is involved in vessel
anastomosis.44 Anastomosis is further facilitated by proangiogenic macrophages, which act as bridging cells between
anastomosing tip cells, and secrete angiogenic growth factors and proteolytic enzymes.45–47 Notch activation in the
macrophages is required for their recruitment to vascular branchpoints and their interaction with endothelial tip
cells.48
2.1.3 Stalk cell proliferation
As mentioned in Section 2.1.1, Notch activation in stalk cells leads to proliferation arrest.49 However, proliferation of
stalk cells is required to elongate the sprout. This is achieved by the expression of Nrarp (Notch-regulated Ankyrin
repeat protein), a negative regulator of Notch signaling that destabilizes the Notch intracellular domain.50 Expres-
sion of Nrarp in stalk cells limits Notch signaling at branch points while promoting Wnt signaling. Wnt, in turn, pro-
motes EC proliferation and vessel stability during sprouting. Interestingly, loss of Nrarp was shown to cause vessel
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regression. Thus, the balance between Notch and Wnt signaling seems to determine whether new vessels are con-
structed or destroyed.51
2.1.4 Vessel maturation
Finally, a functional vascular network requires maturation at the level of the vessel wall but also at the network level.
In the maturation step, ECs stop migrating and proliferating and the barrier function of vessels is restored. Pericytes
play an important role in the stabilization of the nascent blood vessels. They are recruited by PDGF-B, transforming
growth factor (TGF)-𝛽1, and angiopoietin (Ang)-1. Reduced pericyte coverage leads to leaky, unstable vessels and is
associatedwithmetastasis in cancer patients.52 Vesselmaturation is further improved by the deposition of BMaround
the quiescent ECs, called phalanx cells.
Importantly, in tumors, angiogenic factors remain overexpressed and vessel maturation does not occur, resulting
in the typical abnormal and leaky tumor vasculature (reviewed in53). It should also be noted that most insights into
tip and stalk cell phenotype and guidance cues have been obtained in developmental rather than tumor models. To
explore the full translational potential of these molecular findings, additional studies are required to define the role of
these proteins in the cancer setting and, in particular, in metastasis formation.
2.2 Intussusceptivemicrovascular growth (IMG)
Intussusceptive growth or intussusception (i.e., growth within itself) is also known as nonsprouting or splitting angio-
genesis. This concept was first reported in 1986 by Caduff et al.54 in the rapidly expanding postnatal lung vasculature
of rats. In this type of vessel formation, the capillary wall extends into the lumen to split a single vessel in two. Using
electron and confocal microscopy, Paku et al. proposed a mechanistic model for pillar formation, which involves three
consecutive steps. First, intraluminal endothelial bridges are formed. Next, the BM is locally degraded and a bridging
ECattaches to a collagen bundle in the underlying connective tissue. This collagen bundle is transported into the vessel
lumen by pulling forces exerted by the actin cytoskeleton. Finally, maturation of the pillar occurs by invading pericytes
andmyofibroblasts, which deposit new connective tissue.55
Interestingly, this type of blood vessel formation requires only minimal EC proliferation or BM degradation and is
therefore lessmetabolically demanding than sprouting angiogenesis. Moreover, vessels are generatedmore rapidly by
IMG than via sprouting. As such, IMGmay have developed to provide a faster response to a tissue’s oxygen demand.
IMG has been reported in various tumor types, including colon and mammary carcinoma, melanoma, glioma, and
B-cell non-Hodgkin’s lymphoma.56–59 Sprouting angiogenesis and IMGwere even detected simultaneously in a single
mammary tumor nodule.60 Moreover, a switch from sprouting to intussusceptive angiogenesis has been observed in
relapsing tumors after irradiation or treatment with antiangiogenic agents (see chapter 4). Since capillaries formed by
IMG are less leaky and more stable than the typical abnormal tumor vasculature, IMG could be seen as a mechanism
contributing to vessel normalization.13,61 Consequently, rapid vascular remodeling induced by IMG could potentially
improve drug delivery and radiation efficacy.
Several proteins are suggested to contribute to IMG, including VEGF,62 PDGF,63 basic fibroblast growth factor
(FGF2),63,64 Ang-1,65,66 and Erythropoietin.59,67
In the chicken chorioallantoic membrane (CAM), VEGF expressionwas found to be high during sprouting angiogen-
esis, but reduced during intussusception,13,68 suggesting that high concentrations of VEGF mainly induce sprouting,
whereas at lower concentrations, a switch to IMGmay occur. These data, although obtained in a developmental model,
could explain resistance of relapsed tumors after anti-VEGF therapy.
2.3 Vascular co-option
Vascular co-option (reviewed in15) is the mechanism by which tumor cells surround and hijack host vessels resulting
in the incorporation of host–tissue capillaries by the tumor, thereby eliminating the need for new vessel formation.
As such, tumors that predominantly get their blood supply through vascular co-option are also called nonangiogenic
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tumors. Since the “hijacked” vessels are normal host vessels, they lack the typical abnormal features of tumor vascu-
lature, thus providing a better intratumoral blood flow. Vessel co-option occurs mainly in highly vascularized tissues,
such as liver, lungs, and brain. In primary andmetastatic lung cancer and livermetastases even 10–30%of tumorswere
reported to use this alternative blood supply. Consequently, nonangiogenic tumors that appear in these organs are less
likely to respond to antiangiogenic therapy.
Vessel co-option was first extensively studied by Holash et al.69 after implantation of glioma and mammary ade-
nocarcinoma cells in the rat brain, and in experimental lung metastases of Lewis lung carcinoma cells. Although small
tumors were considered to be largely avascular, these authors showed that a subset of tumors rapidly co-opts existing
host vessels to form an initially well-vascularized tumor mass. However, rapid regression of these co-opted vessels by
increased Ang-2 expression led to an avascular tumor and massive tumor cell death. Ultimately, the tumor was res-
cued by VEGF, which in concert with Ang-2 induced robust angiogenesis at the tumor periphery.70 Following studies
showed that VEGF-overexpressing humanmelanoma cells induced rapidly growing brain metastases by dilation of co-
opted, preexisting vessels.71
Vessel co-option has also been demonstrated in non-small cell lung cancer (NSCLC) and lung metastases, derived
from breast, colorectal, and renal cancer cases. 72–75 A prerequisite for nonangiogenic tumor growth in the lungs
appears to be the ability of the tumor to preserve the parenchymal structures of the lung, which can easily be dis-
tinguished on tissue sections. 73 In liver metastases of colorectal carcinomas (CRC), tumor cells were found to replace
hepatocytes, preserving the liver architecture and co-opting the sinusoidal blood vessels.76 This replacement pattern
was evenmore prevalent in breast carcinoma livermetastases, both at the tumor edge and center, andwas not accom-
panied by induction of hypoxia or vascular leakage.77
The above-mentioned studies indicate that, at least in well-perfused organs, tumorsmay growwithout the need for
new blood vessel formation. However, research conducted on this type of alternative blood supply has been limited,
mainly because of difficulties to identify co-opted vessels in the tumor vasculature and todistinguish them fromvessels
that have been formed through angiogenesis.Most studies useCD31, CD34, or vWF staining to quantify angiogenesis.
However, thesemarkers also stain co-opted vessels. Smoothmuscle cell actin (SMA), which stains pericytes that cover
mature vessels, may better distinguish between co-opted and angiogenic vessels since the latter are less mature and
often lack pericyte coverage.78 Double immunostaining using an EC marker and an antibody against Ki67 or prolifer-
ating cell nuclear antigen (PCNA) that detects proliferating cells may also aid in the detection of ongoing angiogenesis.
Alternatively, phase contrast magnetic resonance imaging has been shown to detect vascular remodeling in co-opting
brain.79
In conclusion, additional studies are warranted to understand the mechanism of vascular co-option and to inves-
tigate its impact on antiangiogenic tumor therapy and recurrence of liver, lung, or brain metastases. In particular,
since co-opted vessels are structurally diverse from angiogenic vessels they are likely to be differentially regulated.
It may therefore be expected that these vessels do not respond to the factors that drive angiogenic blood vessel
growth. The latter is also reflected by increased co-option occurring in tumors resistant to antiangiogenic therapy
(see chapter 4).
2.4 Role of EPCs in tumor neovascularization
Accumulating data indicate that EPCs are not only involved in embryonic development but also in adult vasculogenesis
(reviewed in16,17,80). This concept was first demonstrated by Asahara et al. in 1997,81 who isolated circulating cells
with properties of progenitor and ECs from human peripheral blood. These cells (i) differentiated into ECs in vitro and
(ii) contributed to angiogenesis in a mouse model of hind limb ischemia, and were therefore considered to be EPCs. A
subsequent study by these authors showed that bone marrow EPCs not only have therapeutic potential but are also
involved in tumor neovascularization.82 The role of EPCs and vasculogenesis in cancer has since then been extensively
studied.
In physiological conditions, EPCs are maintained in the bone marrow. They reside in a “stem cell niche” exposed to
high local concentrations of the chemokine stromal cell-derived factor 1 (SDF-1/CXCL12), which attracts and binds
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CXCR4-expressing EPCs.83 Also, integrins are involved in the retention of EPCs in the bonemarrow. In particular, inte-
grin 𝛼4𝛽1mediates adhesion of EPCs to fibronectin and vascular cell adhesionmolecule (VCAM)-1.84
The mobilization of EPCs from the bone marrow to the peripheral blood and the tumor site is regulated by various
cytokines and proteolytic enzymes that are released from the tumormicroenvironment.85–87 So far, VEGF/VEGFRand
CXCL12/CXCR4 are considered the key pathways regulating bonemarrow-EPCmobilization.85,86 The EPC-mobilizing
activity of both cytokines is dependent onMMP9,whose expression is inducedbyVEGF. In the initial step of EPCmobi-
lization MMP9 induces the release of EPCs into the circulation.85 VEGF-induced mobilization of EPCs also involves
downregulation of 𝛼4𝛽1 integrin in the bonemarrow.88
EPCs migrate to sites of vascular damage, where they increase vascularization and improve blood flow. Increasing
numbers of circulating EPCs have also been observed in many cancers, including some types of leukemia, lymphoma,
and breast cancer.16 The migration of EPCs to the tumor site is dependent upon chemokine gradients. Once in the
tumor bed, EPCs may either differentiate into ECs or stimulate tumor angiogenesis by producing proangiogenic fac-
tors.
However, the exact role played by EPCs in tumor angiogenesis remains unclear. In particular, the number of EPCs
incorporated intonascent tumorvessels varies between50%toundetectable. Thesedifferences aremost likely related
to the lack of a consensus definition of EPCs. Indeed, EPCs share many markers with hematopoietic stem cells, both
cell linages deriving from a common progenitor, the hemangioblast (for more information see16). Moreover, the defini-
tion of EPC is hampered by the fact that there are two types of cells: proangiogenic hematopoietic cells (early EPCs)
and outgrowth ECs (late EPCs). Also, EPCs from different origins (bonemarrow vs. peripheral blood) express different
markers. As long as the exact definition, origin, and characteristics of EPCs are under debate their role in tumorigenesis
will remain unclear.
2.5 Vasculogenic mimicry
VM refers to the plasticity of cancer cells to form vascular channels. Consequently, tumor cells are directly exposed
to the blood, thus facilitating tumor cell invasion and dissemination. Increased metastasis may explain the correlation
between VM formation inmalignant tumor tissue and poor patient clinical outcome.89 VMwas first described in 1999
byManiotis et al.90 in aggressivemetastatic melanoma and has since then been reported in a variety of tumors, includ-
ing various carcinomas, sarcomas, glioblastomas, astrocytomas, and melanomas.89 In melanoma and glioblastoma the
intratumoral hypoxic microenvironment was suggested to induce the phenotypic switch to VM.91,92
Tumor cells that contribute to VM present a multipotent phenotype. However, unlike embryonic stem cells, these
cells lack critical checkpoint regulation, rendering them highly aggressive.93 Using microarrays it was demonstrated
that melanoma cells that line VM channels show characteristics of both malignant and ECs.94 Recent studies even
indicate the involvement of cancer stem cells (CSCs) in VM (see Section 2.6).
Remodeling of the ECM is critical for the formation of VM channels and to connect these tumor cell-lined vessels to
the ECs of the host vasculature. In particular, themetalloproteinasesMMP2 andMMP14 are crucial for VM formation
by promoting the cleavage of the laminin-5𝛾2-chain into fragments that stimulatemigration and invasion.95 One of the
first proteins thatwas shown tobe involved inVM inaggressivemelanoma isVE-cadherin. VE-cadherin phosphorylates
the epithelial-associated kinase EphA2 (see chapter 3), which increases MMP production. Accordingly, knockdown of
VE-cadherin or EphA2 inhibits VM.96,97
In vivo data attribute an important role for VEGF in VM formation. In melanoma, VEGF/VEGFR1 and downstream
PI3K signaling act in co-operation with integrin-mediated signaling pathways to induce VM.98 In ovarian cancer, VM is
mediated by VEGF-induced expression of EphA1,MMP2, andMMP9.99
In conclusion, VM has been reported in many tumor types and its occurrence is associated with poor clinical prog-
nosis. However, the study of VM is hampered by the lack of methods to clearly distinguish VM vessels from normal
EC lining. Besides the fact that these tumor-derived ECs still express some tumor-specific markers, they are indistin-
guishable fromECs. As such, it has been difficult to link antiangiogenic treatment failure to the appearance of VM-type
vessels. Recent data, which show the involvement of hypoxic, angiogenic, and stem cell pathways (see Section 2.6) in
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VM formation, indicate thatVM-containing tumorsmight bemore sensitive to broad-acting drugs compared to specific
VEGF-targeting agents. In fact, an in vitro differentiation assay suggested that hypoxia, but not VEGF, is an important
factor in the differentiation of glioblastomamultiforme (GBM) tumor cells to ECs.92
2.6 Role of CSCs in tumor neovascularization
CSCs are considered to be major drivers of tumor progression due to their self-renewal capacity and limitless pro-
liferative potential. However, these cells may also promote tumor vascularization by increasing EPC recruitment. A
comparison of rat glioma xenografts containing a high and low fraction of CSCs showed that CSC high tumors express
increased levels of VEGF and CXCL12, which promote the mobilization and recruitment of EPCs.100 CSC-high tumors
also displayed an increasedmicrovessel density (MVD) and blood perfusion. In vitro, CSC-high cultures induced higher
levels of EC proliferation and tube organization comparedwith CSC-low cultures.
Recent studies even raised the possibility that CSCs may also differentiate to ECs and give rise to true endothelial
linings in somehuman cancers, including lymphoma and glioblastoma.101,102 This hypothesiswas supported by the fact
that a subpopulation of ECs within glioblastomas harbors the same somatic mutations as tumor cells, such as amplifi-
cation of the epidermal growth factor receptor (EGFR).101 Moreover, a fraction of CD133+ stem cells is multipotent
and capable of differentiating into tumor and endothelial lineages. Selective targeting of ECs generated by glioblas-
toma stem-like cells (GSCs) inmouse xenografts resulted in tumor reduction, indicating the functional relevance of the
GSC-derived endothelial vessels.102
Moreover, Cheng et al.103 elegantly demonstrated that CSCs may also differentiate into pericytes. Analysis of
humanGBMspecimens using lineage-specific fluorescent reporters showed thatmost pericytes are derived fromneo-
plastic cells. These GSCs are recruited to ECs by CXCL12/CXCR4 signaling and differentiate into pericytes by TGF-
𝛽 . In addition, elimination of GSC-derived pericytes disrupted the vasculature in GBM, resulting in reduced tumor
growth.103,104
CSCs, as identified by expression of the stem cell markers CD133 and CD44 (VE-cadherin), also directly increase
vascularization by VM in aggressive renal cell carcinoma.105 CD133 expression further correlated with VM in triple-
negative breast cancer specimens106 and the GBM cell line U87.107 The mechanism by which CSCs induce VM is not
yet completely understood, but the VEGF/VEGFR2 andNodal/Notch pathways seem to be involved.107,108
3 NOVEL ANGIOGENIC REGULATORS AND CONCEPTS
The molecular dissection of angiogenesis mechanisms has led to the discovery of novel types of angiogenesis regula-
tors (Fig. 2), including proteins involved in bone formation and neurovascular guidance. Meanwhile, microRNAs were
discovered and found to regulate various aspects of EC biology. Finally, EC metabolism has been put forward as the
main engine that drives angiogenic processes. These concepts will be highlighted here.
3.1 Bonemorphogenetic proteins (BMPs)
BMPs belong to the TGF superfamily and consist of about 20 proteins that regulate multiple biological processes in
development andmorphogenesis.5 BMPs are synthesized in the cytoplasmas dimeric precursor proprotein complexes,
which are cleaved by serine endoproteases before secretion.109,110
BMPsignaling ismediatedbyheteromeric combinationsof type1 (ALK1 /SKR3,ALK2/ACTRIA,ALK3/BMPRIA, and
ALK6/BMPRIB) and type 2 (ALK4/BMPRII, ALK5/ActRIIA, ALK7/ActRIIB) transmembrane serine/threonine kinase
type receptors. Upon BMP interaction, the type 2 receptors transphosphorylate the type 1 receptors leading to
the phosphorylation and nuclear translocation of similarity to (the Drosophila gene) Mothers against decapenta-
plegic (Mad) SMAD proteins. BMP receptors can also initiate SMAD-independent signaling, thus increasing the
fine tuning of signals activated by BMPs. Non-SMAD signaling pathways include the phosphoinositide 3-kinase
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F IGURE 2 Novel angiogenesis regulators. Several novel classes of angiogenesis regulators have recently been iden-
tified. (A) BMPs are dimers that bind to heterodimeric combinations of type 1 and type 2 receptors. Upon BMP
interaction, type 2 receptors transphosphorylate type 1 receptors, leading to intracellular signal transduction. BMPs
include proangiogenic (BMP2/4) and antiangiogenic (BMP9/10) members. (B) Four families of axonal guidance lig-
and/receptor complexes are implicated in tumor angiogenesis: (1) Netrins, which bind toDCCorUNC5B receptors, (2)
Slits-roundabout receptors (Robo), (3) semaphorins, which bind plexins and neurophilins (NRP), and (4) Ephrin-Ephrin
receptors (Eph). The extracellular domain of Robo1-3 directly interacts with the Slits, whereas Robo4 requires a core-
ceptor (e.g., Robo1/2 or UNC5B) for slit binding. Plexins are the main receptors for semaphorins, but a subset of the
semaphorins requires the presence of neuropilin coreceptors (Nrp1 and Nrp2). Ephrin-A ligands are attached to the
cell membrane by a GPI linker whereas Bephrin-B ligands are transmembrane proteins. Eph receptors as well as class
B ligands transduce intracellular signaling. (C) Glycolysis and FA oxidation (FAO) have recently been put forward as
major drivers of vessel sprouting. ECs are highly glycolytic and use glucose for energy production. Glucose enters ECs
via glucose transporters (GLUTs) and is converted to pyruvate by a cascade of glycolytic enzymes, including PFKFB3
(6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3). FA enters ECs though FATPs and subsequently enters the
mitochondria though carnitine palmitoyltransferase 1A (CPT1A). FA-derived carbons enter the TCA cycle and are
incorporated in nucleotide precursors for DNA replication. (D) Various microRNAs play a role in vascular remodeling
and angiogenesis. MicroRNAs targeting proangiogenic factors are typically downregulated in cancer, whereas angio-
genic microRNAs stimulate angiogenesis by reducing angiostatic signals. Angiogenesis is further regulated by tissue-
specific and/or hypoxia-inducedmicroRNAs.
(PI3K)-Akt-mTOR pathway, the small GTPases Rho, Rac, and Cdc42, and the Ras-Erk-Mitogen-activated protein
kinase (MAPK) pathway.111,112 BMP signaling may be affected by membrane-associated coreceptors including
Bambi, DRAGON, ROR2, Endoglin, and Betaglycan (TbetaRIII).113–115 The latter two lack kinase activity but regu-
late vascular development by increasing the binding of BMPs and by modulating BMP receptor trafficking and cell
localization.116,117
Beyond their importance in embryonic development, BMPs exert proangiogenic roles in vitro and in vivo directly
by activating ECs, or indirectly by inducing the expression of other proangiogenic factors. BMP2/4/6/7 stimulate
ECs to proliferate, migrate, and to reorganize in tube-like structures via the activation of SMAD1/5, Erk 1/2, and Id1
expression.118–121 In vivo, recombinantBMP2/4 enhance angiogenesis in the chickenCAMassay and inMatrigel plugs.
BMP2/4 further induce a large increase in the size and number of blood vessels in different murine tumormodels, act-
ing early in the establishment of a tumor’s blood supply. 122,123 In several physiological and pathological conditions
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BMPs influence the vasculature in an indirect way by regulating the expression of growth factors and their receptor(s)
including VEGF, FGF, VEGFR2, and VEGFR1.124–126
BMP9 and BMP10 instead mainly mediate the late phases of angiogenesis, as they suppress EC migration and
proliferation.118 These BMPs are functionally equivalent ligands of the endothelial-specific receptor ALK1. They are
supplied via the bloodstream (2 and 12 ng/mL in healthy humans) and are in constant interaction with the apical
side of ECs where they control quiescence of adult blood vessels.127–130 During embryogenesis, two distinct func-
tions of BMP10 have been described. BMP10 supports vascular development via ALK1-dependent signaling in ECs,
which can be functionally substituted by BMP9. On the other hand, BMP10 regulates heart development in a BMP10-
exclusive manner. In postnatal vascular development both ligands serve a redundant role.131,132 BMP9 and BMP10
prevent VEGF and FGF2-induced sprouting angiogenesis in vitro and in several in vivo assays, including Matrigel
plug assay, CAM assay, and developmental retinal neovascularization in vivo via activation of downstream SMAD
1/5 pathways.133 BMP9 not only inhibits angiogenesis but also destabilizes already formed vessels.130 Moreover, the
BMP9/ALK1 pathway inhibits neovessel formation inmousemodels of age-relatedmacular degeneration.134
Recently, particular attention was reserved to BMP9/10-ALK1 signaling as an alternative target for the develop-
ment of antiangiogenic therapies (reviewed in135,136). ALK1 is widely expressed on prostate, skin, thyroid, kidney,
ovary, lung, pancreas, and liver tumor blood vessels. Anti-ALK1 can decrease tumor growth and angiogenesis when
combined with a VEGFR inhibitor in a human/mouse chimera tumor model.137 Two main pharmacological inhibitors,
an ALK1-Fc fusion protein (Dalantercept/ACE-041),138–140 which serves as BMP9 (and BMP10) ligand trap, and a fully
human antibody against the extracellular domain of ALK1 (PF-03446962)141–143 are currently under clinical develop-
ment for cancer treatment.
3.2 The neurovascular link: Axon guidancemolecules
While studying the angiogenic process at a molecular level, a strong resemblance was noted between vessel sprout-
ing by tip cells and neural development/axon guidance. Four canonical families of axon guidance cues implicated
in tumor angiogenesis are distinguished: netrins, which binds distinct receptor types (deleted in colorectal cancer
(DCC) orUNC5homologs); semaphorins,which bind plexins andneuropilins; Ephrins-Ephrin receptors (Eph); and Slits-
roundabout receptors (Robos).3,4 Here we focus on their function in (tumor) angiogenesis.
Although the netrins were the first axon guidance molecules to be identified, the role of netrin 1 and netrin 4
in angiogenesis has yet to be understood since contradictory results have been obtained in vitro and in vivo.144,145
Besides, expression of netrin 1, themost studied netrin, has only been demonstrated in few tumors, although its recep-
tor UNC5B is strongly expressed in tumor blood vessels.144
3.2.1 Slits and robo receptors
Slits are secretedECMproteins that share ahighdegreeof structural conservation. Inmice andhumans threeSlits have
been identified (Slit1, Slit2, and Slit3).146 In order to gain axon guidance function Slits need tobeproteolytically cleaved
to release the active Robo-binding N-terminus.147 The effect of SLIT processing on endothelial receptor activation is
not yet clear.148
The Robo family of receptors is highly conserved through evolution. In mammals four Robo receptors are present:
Robo1/Dutt1, Robo2,Robo3/rig1, andRobo4/magic roundabout.146 WhileRobo1-3 contain ahighdegreeof structural
and functional similarity, theextra- and intracellular domainofRobo4 is smaller andRobo4acts distinctly.3 Robo recep-
tors belong to the immunoglobulin (Ig) superfamily of cell adhesion molecules. The extracellular domain of Robo1-3
interacts with the Slits, whereas Robo4 requires a coreceptor as it does not directly bind Slit ligands. This corecep-
tor might be a heparan sulfate proteoglycan (e.g., Syndecan), Robo1, Robo2, or UNC5B (the chemorepellent recep-
tor of Netrin-1).149–152 Proteoglycans also stabilize interactions between Slits and Robo1-3 and heparan sulfate gly-
cosaminoglycans concentrate and localize Slits in the tissue.153,154 Robo1andRobo4are expressed inECs and regulate
both physiological and pathological angiogenesis.155
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Robo4−/− mice display normal vessel patterning.152,156 However, during pregnancy, Slit/Robo4 signaling is involved
in regulation of the vascular network in the mammary gland when angiogenesis is stimulated by VEGF.155 The proan-
giogenic action of VEGF is in this process balanced by Slit/Robo4 interaction, through inhibition of lamellipodia
formation.157 Robo4maintains thebarrier functionofmature vessels by inhibiting angiogenic factor-induced endothe-
lial hyperpermeability.156 Consequently, high expression of Robo4 correlates with a favorable prognosis in early-stage
lung cancer.158
Slit2 signaling through Robo1 and Robo2 mediates pathological retinal neovacularisation.159 Blockade of Robo1
by a neutralizing antibody reduces MVD and tumor growth of xenografted melanoma cells160 and chemical-induced
squamous cell carcinogenesis.161 Whereas normal and hyperplastic buccal mucosa express Slit2 minimally, its expres-
sion is drastically upregulated in neoplastic mucosa where it correlates with increased tumor angiogenesis.161 Slit2
mRNA is expressed in multiple human cancer cell lines and in cancer tissue.160 The promoter region of Slit2 is fre-
quently hypermethylated in lung and breast cancer reducing Slit2 expression and suggesting a tumor-suppressive
role for Slit2.162 Thus, Slit2 affects both endothelial and tumor cells and may elicit endothelial stimulatory as well
as inhibitory actions. This attracting versus repellent action is typical for members of the axon guidance family. In
the case of Slits it is at least partly caused by differential receptor activation. Robo1, which directly interacts with
Slits, promotes endothelial motility.150 In contrast, Robo4 that needs a coreceptor for Slit-induced signaling induces
endothelial repellence and, in counteraction of VEGF, provides vascular stabilization.156,163 In addition to differ-
ential expression or activation of Robo1/2 versus Robo4 on ECs, other explanations have been proposed for the
angiogenic versus angiostatic effect of Slits148: (1) the need for a cofactor enforcing the angiostatic effect,147,164,165
(2) agonistic versus antagonistic effects of the N-terminal fragment of Slit versus full-length Slit, and (3) a cell-
dependent processing of Slit.147,164 Additional research on Slit2/Robo signaling in ECs will hopefully provide a unified
concept.148
Thus, based on their altered expression in a wide variety of cancer types and their regulatory function on vascular
networks, Slits and Robos might serve as targets for cancer treatment. However, their bifunctionality, that is, opposite
functions depending on the cellular circumstances, represents a major challenge. In addition, careful drug targeting to
the tumor will be needed, because interruption of normal Slit/Robo signaling in nearby tissues could have deleterious
effects.146
3.2.2 Plexins, neuropilins, and semaphorins
Like Slit proteins, semaphorins aremultifaceted regulatory signals involved in physiological and pathological angiogen-
esis. Their receptors are expressed on tumor cells,monocyte/macrophages, andECs in the tumor stroma. As regulators
of tumor angiogenesis, tumor growth, cancer cell invasiveness, andmetastatic spreading, they are potential therapeu-
tic targets in cancer.
In vertebrates, the semaphorin family contains around 20 genes that are classified based on common struc-
tural features of the encoded proteins.4,166 All semaphorins contain a typical sema domain, harboring sites for
semaphorin dimerization and receptor binding, which is located close to the N-terminus. This domain is also present
in the semaphorin receptors of the plexin family. Class 3 semaphorins are secreted, whereas other semaphorins are
membrane-anchored or transmembrane proteins that can be further processed into soluble forms by specific pro-
teases. The active forms of several class 3 and class 6 semaphorins are homodimers.167–169
Plexins are the main receptors for semaphorins, but a subset of the class 3 semaphorins requires the presence
of obligate coreceptor molecules, called neuropilins (Nrp1 and Nrp2).4 The latter are also coreceptors for VEGFs.
Plexins are devoid of TK activity, but are able to activate RTKs (including VEGFR2, FGFR2, and EGFR) in “trans.”170
Multiple semaphorins have been associated with modulation of the tumor vasculature (recently reviewed by166,
including Sema3A, Sema3E, Sema3F, and Sema3G (as inhibitory signals) and Sema4D and Sema6D (as proangiogenic
factors)).
Sema3A is an inhibitor of developmental angiogenesis.171,172 Downregulation of its expression in many types
of solid tumors annihilates its negative impact on angiogenesis.173–175 Also angiostatic Sema3F is downregulated
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during tumor progression.175–177 Systemic and tumor-targeted delivery of Sema3A stabilizes the tumor vasculature
and inhibits tumor angiogenesis, metastasis, and tumor growth in multiple mouse models, supporting further investi-
gation of Sema3A-based anticancer therapy.178
Some semaphorins seem to control the recruitment and activation of leukocytes. Soluble Sema4A and Sema7A
chemoattract and activate monocytes/macrophages inducing the release of proinflammatory and proangiogenic
molecules (e.g., CXCL8 or VEGF).179–181
Usually, semaphorin signaling pathways lead to inhibition of migration,4 however, Sema4D/CD100 and Sema6D
are angiogenic. Sema4D is a membrane-bound protein expressed in tumor cells, tumor-associated macrophages
(TAMs),182 and platelets, but the extracellular domain can be cleaved and released from producer cells by MMPs. Sol-
uble Sema4D retains the biological activity of membrane-bound Sema4D. Binding of Sema4D to plexin-B1 stimulates
angiogenesis directly through activation of plexin-B1 and the downstream signaling pathways PI3K/Akt, Rho, and NF-
kB, and indirectly via transactivation of the hepatocyte growth factor (HGF) receptor Met.183 Angiogenic Sema6D
signals through Plexin-A1, which forms complexes with, and activates, VEGFR2.184
3.2.3 Ephrins and ephrin receptors (Eph)
TheEph (erythropoietin-producinghepatocellular carcinoma) receptors,whichareTKs, and theirmembrane-anchored
ephrin (Eph receptor interacting protein) ligands form two large families.185,186 Ephrin-A ligands are attached to the
cell membrane via a glycosylphosphatidyl-inositol (GPI) linker, whereas ephrin-B ligands are transmembrane proteins.
The receptor–ligand interactions are highly promiscuous.187 Remarkably, both the receptors and the Class B ligands
transduce intracellular signals. Classical forward signaling (i.e., RTK signaling) is activated by an ephrin through its Eph
receptor on a neighboring cell. Reverse signaling occurs when a Class B ephrin mediates (after interaction with its
receptor) signaling in the cell on which the ephrin is expressed. In many cases forward signaling leads to repulsion of
the Eph-expressing cell. However, a repulsive Eph-ephrin pair can in other circumstances also promote adhesion. Of
note, transmembrane semaphorins (Classes 4 and 6) may also transduce reverse signals.170
Strong genetic evidence supports an essential role for ephrin-B2 and EphB4 in the development of blood and lymph
vessels during embryogenesis.188–191 In addition, ephrin-B2 assists in stabilization of vessel walls during vascularmat-
uration allowing cell spreading and focal adhesion.192
Besides regulating embryonic vessel formation, ephrin-B2 and EphB4 play a role in neovascular eye disorders.185
Furthermore, several Eph receptors and ephrin molecules are upregulated in tumors and may affect tumor growth
and vascularization. For instance, EphA2 and its ligand ephrin-A1 are expressed in breast, ovarian, prostate, lung, and
skin cancer.187,193 In breast tumor cells overexpressing EphA2, EphA2 signals in a ligand-independent fashion through
crosstalk with EGFR and HER2, thereby promoting tumor growth.194 In the tumor environment, expression of EphA2,
which is absent on quiescent vasculature, is induced in ECs via interaction with ephrin-A1 present on tumor ECs and
tumor cells. Subsequent forward signaling through EphA2 stimulates angiogenesis195 and vascular permeability.196
Blocking EphA receptor activation or gene deletion in mice reduces the size and vascularization of experimental
tumors.197 Similarly, high expression of ephrin-B ligands and EphB receptors in some human cancers correlates with
poor prognosis.198,199 Ephrin-B2, which is upregulated in ECs by hypoxia and VEGF, is expressed on the blood vessels
of many tumors.195 Through activation of ephrin-B2 on ECs, tumor cell expressed EphB4 promotes angiogenesis.200
Several approaches targeting the activity of ephrin-B2 and/or EphB4 reduced the growth and vascular network of
tumors.201,202 However, certain Eph receptors exert tumor-suppressive activity203 and therefore more research is
needed to exactly decipher the signaling pathways and activities of Ephs and ephrins in specific cell or cancer types.
3.3 miRNAs asmaster regulators of tumor angiogenesis
MicroRNAs (miRs) are short (∼22-nucleotides in length) endogenous noncoding RNAs that were discovered in ver-
tebrates in 2001.204 They negatively regulate the expression of target genes at a posttranscriptional level, thereby
affecting many cellular processes.205,206 MiRs promote the cleavage of the target mRNA or inhibit its translation
through complementary base pairing at the 3′ untranslated region (UTR).207 Expression of miRs is strictly regulated in
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a time- and tissue-specific manner, allowing cell-specific functions. Since 2008, an increasing number of miRs has been
identified that regulate the expression of angiogenic factors or interfere with angiogenic signaling pathways (for an
overview, see Table I and reviewed in6).
MiRs targeting proangiogenic factors are typically downregulated in cancer,whereas angiogenicmiRs reduce angio-
static proteins. As such, both can contribute to the angiogenic switch during cancer progression. Interestingly, miR
expression may be transcriptionally controlled by (anti)angiogenic proteins, adding further complexity to miR-based
angiogenesis regulation.
3.3.1 Endothelial-specificmiRs: miR-126
Some miRs are endowed with tissue-specific actions. A crucial player in EC biology is miR-126, which is specifi-
cally enriched in ECs and EPCs. During embryonic vasculogenesis, miR-126 maintains vessel integrity by enhancing
the proangiogenic activity of VEGF and FGF, via suppression of negative regulators of the Ras/MAPK and PI3K/Akt
pathways.260,261 However, miR-126 also binds to the 3′UTR of VEGF mRNA, thereby reducing the expression of
VEGF.247 As such, its role in tumor growth is not clear and, depending on the tumor type, it may elicit a tumor-
promoting or suppressing function (reviewed in262).
miR-126 is downregulated in several cancer types, including lung,263 breast,264 colorectal,265 and gastric cancer247
by promotermethylation of its host gene, EGF-like domain 7 (Egfl7).265,266 A correlationwas shown betweenmiR-126
downregulation and poormetastasis-free survival of breast cancer patients.266 Moreover, downregulation ofmiR-126
was found to correlatewith increasedMVDandVEGFexpression in gastric cancer tissues.247 Conversely,miR-126was
shown to suppress EC recruitment tometastatic breast cancer cells,metastatic angiogenesis, and colonization through
coordinate targeting of novel proangiogenic genes and biomarkers of humanmetastasis (i.e., insulin-like growth factor
binding protein 2, PITPNC1, and c-Mer tyrosine kinase).267
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3.3.2 Cell-type and context-dependentmiR: miR-17-92
The miR-17-92 cluster was among the first miRs that were linked to tumor angiogenesis. miR-17-92 is a polycistronic
miR cluster that containsmultiplemiRs (miR-17,miR-18a,miR-19a/b,miR-20a, andmiR-92a). Eachof thesemiRs holds
the potential to regulate several targetmRNAs. As such, the functions of this miR cluster are very diverse and cell type
and context dependent. miR-17-92, also called oncomir-1, is upregulated by the transcription factor Myc in several
cancers.268,269 Thrombospondin (TSP)-1, one of the main endogenous inhibitors of angiogenesis, is targeted by miR-
19.268,270 Consequently, miR-17-92-transduced tumor cells form larger and better perfused tumors, which correlate
withdownregulationofTSP-1.268 Recently, treatmentofECswithVEGFwas shown to trigger theexpressionof allmiR-
17-92 cluster members by activation ofMAPK and the transcription factor Elk-1 (member of the E26 transformation-
specific (ETS) oncogene family), which binds to the miR-17-92 cluster promoter sequence. This resulted in repression
of PTEN (phosphatase and tensin homolog), a tumor suppressor that inhibits Akt/PI3K signaling. Consequently, VEGF-
induced miR-17-92 cluster expression contributes to the angiogenic switch of ECs and was found to be essential for
EC proliferation and sprouting.271
However, in an in vivo setting, miR-17-92 biology is likely to be more complex, and dependent on the regulation
of individual (pro- and antiangiogenic) members of this cluster as well as non-EC-derivedmiR-17-92 cluster members.
Indeed,miR-17-92alsoelicits antiangiogenic activity by targetingTGFBR2,VEGF, and the transcription factor hypoxia-
inducible factor (HIF)-1𝛼 in colorectal cancer.223 Moreover,whereasmiR-17/20 exhibits antiangiogenic activity in ECs,
it does not affect tumor angiogenesis, indicating a context-dependent regulation.272
3.3.3 miRs Regulate Cellular Adaptation to Hypoxia
Further experimental evidence suggests thatmiRs are important components of cellular adaptation to hypoxia. A num-
ber ofmiRs are upregulated byHIF-1𝛼. The predominant hypoxia-induciblemiR ismiR-210. HIF-1𝛼 binds to a hypoxia-
response element (HRE) on the proximal miR-210 promoter. MiR-210 target genes can be classified into five major
functional categories: mitochondrial metabolism, cell cycle control, angiogenesis, apoptosis, and DNA damage repair.
Expression of this hypoxamiR is greatly induced in pancreatic, breast, head and neck, lung, colon, and renal cell lines
after exposure to hypoxia.273 Furthermore, miR-210 expression has been linked to bad prognosis in patients with soft
tissue sarcoma, breast, head and neck, and pancreatic cancer (reviewed in274,275). miR-210 also emerged as a potential
therapeutic target in diffuse large B-cell lymphoma.276
Whereas miR-210 is widely expressed, other miRs respond to decreased oxygen tension in a more tissue-specific
manner. Moreover, HIF-1𝛼 expression itself is regulated by several miRs, such as miR-497 in breast carcinoma,224
adding another level of complexity to the classic hypoxia-regulated gene network.
3.4 ECMetabolism
The role of ECmetabolism in tumor angiogenesis has been completely overlooked during the past 40 years. Still, recent
concepts indicate that angiogenesis is not only regulated by the balance between pro- and antiangiogenic factors, but
also by changes in EC metabolism (reviewed in7). Indeed, activated ECs rapidly switch from quiescence to angiogenic
sprouting and must be able to adjust their metabolism accordingly. Thus, metabolic changes may significantly impact
EC behavior and activity.
3.4.1 Glucosemetabolism
Despite their privileged position having direct access to oxygen in the blood, ECs from macro- and microvessels rely
primarily on glycolysis (generating around 85% of their ATP content through this pathway) rather than on mitochon-
drial respiration to generate energy.277 In particular tip cells need a high rate of glycolysis.
Glucose enters ECs via glucose transporters (GLUTs) and is converted to pyruvate by a cascade of glycolytic
enzymes. Proangiogenic signals like VEGF and FGF2 increase the expression of GLUT-1 as well as that of main
glycolytic enzymes, such as PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3). Moreover, PFKFB3
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harbors hypoxia-response elements and is a target of HIF-1𝛼. Accordingly, knockdown of PFKFB3 in ECs reduces vas-
cular sproutingby impairing tip cellmigrationand stalk cell proliferation,without affecting theexpressionof angiogenic
factors.277,278
Glycolytic intermediates may also be shuttled into other metabolic pathways, including the pentose phosphate
pathway (PPP) and hexosamine biosynthesis pathway (HBP). The PPP pathway uses glucose-6-phosphate to generate
NADPH for redox control and lipid synthesis and ribose-5-phosphate for nucleotide synthesis. Tumor ECs upregulate
genes involved innucleotide synthesis and shunt glucosemetabolites tonucleotidepathways to assure sufficiently high
nucleotide pools for cell duplication. NADPH reduces oxidized glutathione, a key cellular oxidant, thereby protecting
ECs against oxidative stress.279 The HBP pathway produces N-acetylglucosamine for protein O- and N-glycosylation.
Posttranslational glycosylation status determines the activity and structure of several angiogenic proteins, including
Notch,280 VEGFR,281 andMMPs.282 Each of these pathways is important for angiogenesis as its genetic or pharmaco-
logical inhibition reduces EC viability, migration, and/or angiogenesis.280,283–285
In addition, recent findings highlight the inhibition of c-MYC mediated by FOXO1 (Forkhead box protein O1) as
a key mechanism that decelerates metabolic activity of ECs and controls quiescence. MYC ablation impairs glycolysis,
mitochondrial function, and proliferation of ECs. Conversely, EC-specific overexpression ofMYC fuels these processes,
and restoration ofMYC signaling in FOXO1-overexpressing endothelium normalizes metabolic activity and branching
behavior.286
3.4.2 Fatty acidmetabolism
Besides glucose, fatty acids (FAs) represent an important fuel source for ECs. FAs enter the cell throughdifferentmech-
anisms, including membrane-associated FA transport proteins (FATPs), and associate with cytosolic FA-binding pro-
teins (FABPs), which chaperone FAs inside the cell.287 Proangiogenic signals (VEGF and FGF2) upregulate the expres-
sion of FATPs and FABPs, which are required for EC proliferation and sprouting.288 Recently it has been clarified that,
unlike inmost normal and cancer cell lines, FA oxidation (FAO) contributesminimally (less than 5%) to ATP synthesis in
ECs. Instead, FAOprovides carbons for de novonucleotide synthesis via the tricarboxylic acid (TCA) cycle, thereby pro-
moting EC proliferation and sprouting angiogenesis.289 Carnitine palmitoyltransferases (CPTs), more precisely CPT1,
catalyze the transesterification of long-chain FA-CoA and its transport into the intramitochondrial matrix, thus regu-
lating the rate of FAO. CPT1A is the most abundant isoform in ECs. Its deficiency impairs sprouting and proliferation
without altering ATP levels or oxygen consumption.289
In conclusion, recent data indicate thatmetabolic reprogramming, a crucial hallmark of cancer that shifts metabolic
pathways to enable sustained growth of cancer cells, also applies to tumor ECs. Consequently, blocking the EC engine
might prove more effective than blocking individual drivers, such as VEGF. However, it should be noted that energy
production depends on nutrient availability. As such, EC metabolism is modulated by the metabolic program of other
cell types in the tumor microenvironment. Accordingly, recent data show that hypoxic TAMs compete with tumor ECs
for glucose.290
4 ANGIOGENESIS IN PRACTICE: CLINICAL IMPLICATIONS
The clinical usage of antiangiogenic agents targeting VEGF/VEGFR has shown that the anticancer potential of these
drugs is limited and associated with unexpected side effects and tumor resistance, or even the occurrence of more
aggressive tumor cells and increased metastasis. Accumulating evidence indicates that these adverse effects may be
induced by the expression and activation of alternative angiogenic factors and pathways, the appearance of hypoxia-
tolerant or vessel-independent tumor cells or a tumor vasculature that arises in the absenceof angiogenesis.Moreover,
as novel mediators continue to be discovered, it is clear that the multifactorial nature of neovascularization requires
tackling the process at different levels. Various resistance mechanisms and potentially improved treatment options
and/or schedules will be discussed here.
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4.1 Why antiangiogenic therapy fails to treat cancer
During the past 10 years, angiogenesis inhibiting drugs have been tested (i) in the adjuvant setting after sur-
gical removal of the primary tumor to prevent local relapse or the growth of micrometastases or (ii) in the
neoadjuvant setting to downsize nonresectable to potentially resectable tumors. In most settings, antiangio-
genic agents such as bevacizumab and aflibercept (which are classical VEGF-traps) only showed significant activ-
ity when combined with cytotoxic chemotherapy, while tyrosine kinase inhibitors (TKIs) also worked as single
agents.
Despite the increasing number of data and drug candidates, resistance to antiangiogenic therapy remains a chal-
lenging issue that is associated with variable success in the clinic and with poor prognosis for cancer patients. Several
mechanisms can account for this therapeutic failure.291
4.1.1 Activation of alternative proangiogenic pathways
Besides VEGF, several additional pathways are implicated in tumor growth and cancer-associated angiogenesis.
These alternative ways can sustain tumor growth and blood vessel survival even in response to VEGF/VEGFR
blockade.
Inhibition of VEGFR2 in a mouse model of pancreatic cancer resulted after an initial response in tumor regrowth,
accompaniedby increasedvascularizationandaugmented levels of proangiogenic factors likeFGF2,Ang-1, andephrin-
A1.292 Likewise, FGF2, CXCL12, and placenta growth factor (PlGF) were upregulated in progressive glioblastoma
growth after treatment with the pan-VEGFR TKI AZD2171.293 Together with the “alternative” proangiogenic factors
mentioned above several other players have been identified in preclinical studies such as EGF, FGF1,Dll4, HGF, CXCL8,
and PDGF-C. 294 Accordingly, increased serum levels of FGF2, HGF, PlGF, and CXCL12 have been observed in patients
treatedwith antiangiogenic agents just before tumor progression and acquisition of resistance.295 These observations
reinforce the rationale for simultaneous targeting of multiple angiogenic drivers. However, the majority of TKIs used
to treat patients aremultitargeting drugs that nevertheless failed to treat different types of tumors.296,297
4.1.2 Recruitment of proangiogenic stromal cells
The tumor microenvironment contains a heterogeneous and complex mixture of stromal cells (fibroblasts, pericytes,
endothelial, mesenchymal, and hematopoietic cells) that actively support tumor growth and are associated with resis-
tance to anti-VEGF therapy.298
Antiangiogenic as well as vascular disrupting agents (VDAs), which cause acute hypoxia, trigger the recruitment
of EPCs and immune cells to the tumor margins. Various preclinical models strongly suggest a role for neutrophils in
mediating tumor angiogenesis and refractoriness to anti-VEGF therapy. Tumor-associated neutrophils (TANs)mediate
the angiogenic switch in different tumor models, by producing various growth factors (including VEGF) and secreting
activeMMP9 that releases FGF2 andVEGF from the ECM.299 Also the clinical evidence supporting this notion is grow-
ing. In myxofibrosarcoma patients, elevated numbers of neutrophils positively correlate with tumor MVD. Moreover,
intratumoral infiltration of neutrophils is significantly associated with tumor grade in glioma patients.300 In NSCLC
patients treated with chemotherapy plus bevacizumab, a high number of circulating neutrophils and monocytes and a
high neutrophil-to-lymphocyte ratio are associated with poor clinical outcome.301
In the last decade a tumor-promoting role has also been attributed to TAMs. Despite their potential role in anti-
tumor immunity, high frequencies of TAMs correlate with poor prognosis in most human cancers.302 TAMs have
proangiogenic activity, and macrophage infiltration in tumors is generally associated with high vascular density.303,304
Indeed, TAMs infiltrating established tumors acquire an “M2-like” phenotype endowed with promotion of tumor
growth and angiogenesis, remodeling of tissues, and suppression of antitumor immunity.304 M2-like TAMs accumulate
in hypoxic tumor areas and display strong proangiogenic activity through the expression of various angiogenic growth
factors, cytokines, and proteases.305
Furthermore, many other stromal subpopulations may be present or recruited at the tumor site during tumor
growth or in response to antiangiogenic treatment. In particular, immature myeloid cells or EPCs that produce growth
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factors or physically incorporate into tumor blood vessels have been detected in the tumor microenvironment, where
theymay foster resistance to antiVEGF therapy.306,307
4.1.3 Alternativemechanisms of tumor vascularization
As mentioned in Chapter 2, tumor vascularization may occur through different mechanisms (Fig. 1), each with its spe-
cific characteristics and regulators.308
IMG occurs in various tumor types, and is increased in relapsing tumors after irradiation or antiangiogenic
treatment.309–315 In hepatocellular carcinoma xenografts treated with the mTOR inhibitor sirolimus, IMG was
observed during treatment and early recovery phase, whereas in control animals the capillary plexus mainly extended
by sprouting.311 Similarly, treatment of mammary carcinomas in mice by radiation or the VEGFR inhibitor PTK787
resulted in transient reduction of tumor growth, followed by post-therapy relapse accompanied by IMG.309 Compa-
rable observations were made in the RIP-Tag2 and Lewis Lung carcinoma models treated with inhibitors of VEGFR
signaling and in renal cell carcinoma312 and melanoma models treated with TKIs.316 These data suggest that IMG
represents a tumor-protective response to cancer therapy to preserve the intratumoral vasculature. Moreover, the
mechanism of IMG is very different from sprouting, indicating that other therapeutic strategies will have to be
followed.
Vessel co-option mainly occurs in tumors and metastases of highly vascularized tissues (see Section 2.3). Treat-
ment of mice bearing brain metastases of VEGF-overexpressing melanoma cells with the VEGFR2 TKI ZD6474
showed, despite effective blockage of angiogenesis, sustained tumor progression via co-option.317 In glioblastoma-
bearing mice, an anti-VEGF antibody prolonged survival but increased vascular co-option.318 Also in an ortho-
topic human hepatocellular carcinoma (HCC) model, tumors resistant to sorafenib (the TKI approved for systemic
therapy of HCC) became more invasive, which facilitated the co-option of liver vessels. Interestingly, whereas
24% of the total vessels were provided by co-option in untreated tumors, this number reached up to 75%
in sorafenib-resistant tumors, thus providing the first evidence that vessel co-option is responsible for resis-
tance to antiangiogenic therapy.319 Also in melanoma metastases taken at clinical relapse in patients under-
going adjuvant treatment with bevacizumab, a mature intratumoral network with low angiogenic activity was
noted.320 Vessel co-option is also associated with resistance to sunitinib in preclinical lung metastasis models75
and with a poor response to bevacizumab in patients with CRC liver metastases.321 Moreover, combined inhi-
bition of angiogenesis and vessel co-option was found to be more effective than the inhibition of angiogenesis
alone.321
4.1.4 Vascular independence of tumor cells
A prerequisite for the anticancer potential of antiangiogenic agents is the vascular dependence of tumors. However,
recent data indicate that tumor cells are heterogeneous in their dependenceonneighboring tumor-associated vascula-
ture for survival. Some cancer cells are highly vessel dependent, whereas others can survive inmore hypoxic regions of
tumors, distal from tumor vessels.Moreover, long-term antiangiogenic therapymay result in the outgrowth of subpop-
ulations of less angiogenesis-dependent malignant cells with an increased capacity to survive in nutrient- or oxygen-
deprived tumor areas.322,323
Severalmechanismsmay account for the vascular independence of tumor cells. It has been reported thatmice bear-
ing p53-deficient (p53−/−)HCT116humanCRC tumors are less responsive to antiangiogenic combination therapy than
mice bearing isogenic p53+/+ tumors.324 Alternatively, a metabolic switch in cancer cells may occur, as reported in a
mousemodel of breast cancer treatedwith the TKIs nintedanib or sunitinib. After an initial regression, tumors became
resistant and resumed growth in the absence of tumor angiogenesis. Distal cells located in avascular areas underwent
metabolic reprogramming toward a hyperglycolytic state producing lactate, which was utilized by tumor cells in the
vicinity of blood vessels for oxidative phosphorylation.325
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Altogether these observations confirm that, even if antiangiogenic therapy targets genetically stable ECs in the
tumor vasculature, genetic alterations or metabolic switches that decrease the vascular dependence of tumor cells
can influence the therapeutic response of tumors to this therapy.
4.2 Hypoxia induces amore aggressive and resistant tumor type
Hypoxia is one of the main features of solid tumors, and correlates with poor prognosis of cancer patients.326
Reduced oxygenation of the tumor tissue is also acknowledged as a main cause of resistance to chemo- and
radiotherapy. Intratumoral hypoxia can confer chemoresistance by (i) affecting drug delivery and cellular uptake
through associated acidity, (ii) upregulation of multidrug resistance protein (MDR) expression, or (iii) by the fact
that a number of chemotherapeutics require oxygen to exert their cytotoxic activity.327 Resistance to radiother-
apy is mainly caused by reduced generation of reactive oxygen species (ROS) and decreased DNA damage.328
In general, radio- and chemotherapy preferentially target rapidly proliferating tumor cells. However, the most
resistant cells are quiescent, slowly proliferating, stem-like cell fractions residing in the most hypoxic tumor
region.329,330
The original paradigm of tumor growth stated that tumors cannot survive or grow in conditions of hypoxia,
such as induced by antiangiogenic therapy. However, after treatment with VEGF blockers a proportion of hypoxia-
tolerant cancer cells survives in poorly oxygenated niches and adapts to antiangiogenesis by increasing various cellular
survival processes.331 Moreover, dysfunctional tumor vascularity and heterogenic blood supply cause oxygen fluc-
tuations with sporadic reoxygenation periods in cancer.332 Cells reoxygenated after acute hypoxia may undergo
rapid p53-dependent apoptosis. Consequently, cells that lack functional p53 are even more prone to further
genomic instability, and potentially tumorigenesis, if they experience reoxygenation after acute exposure to
hypoxia.333
Hypoxia results in the activation of HIFs. These transcription factors are master regulators of O2 homeostasis that
mediatemany transcriptional changes in response to lowO2 tension.HIF-1 consists of a constitutively expressed𝛽 sub-
unit and an O2-sensitive 𝛼 subunit that is rapidly degraded in normoxic conditions. Degradation involves recognition
by prolyl hydroxylase domain (PHD) enzymes, binding to the vonHippel–Lindau (VHL) tumor suppressor protein, ubiq-
uitination, and proteasomal degradation.334 Under hypoxic conditions, PHD activity is attenuated, leading to HIF-1𝛼
protein stabilization, dimerization with HIF-1𝛽 , and translocation into the nucleus. The binding of the HIF-1𝛼/𝛽 het-
erodimer to hypoxia response elements (HREs) subsequently induces the transcriptional activation of various genes
involved in angiogenesis, metastasis, apoptosis, and glycolysis.335 As an example, in clear cell renal carcinoma loss of
function of the VHL gene, which is responsible for ubiquitination and degradation of HIF-1𝛼, leads to the upregulation
of HIF responsive genes, such as PDGF and VEGF.336
Nevertheless, the HIF pathway can also be activated in a hypoxia-independent manner by epigenetic changes and
mutations that lead to a loss of tumor-suppressor functions and/or a gain of oncogene functions, or in response to
cytokines and growth factors.337 It is worth to remember that HIF-1𝛼 and nuclear factor kappa B (NF𝜅B) together
govern the malignant and metastatic phenotype of cancer cells through the regulation of a plethora of genes involved
in cell survival, migration, invasion, metabolism, and neovascularization.338
Overall, hypoxia induces an imbalance in the production of pro- and antiangiogenic factors, which leads to
enhanced, rapid, and chaotic blood vessel formation. In particular, hypoxia and HIF-1/2𝛼 have been shown to be
directly involved in all steps of blood vessel formation. Hypoxia induces the recruitment of EPCs from the bone mar-
row and their differentiation into ECs.339 HIF-1/2𝛼 stimulate EC proliferation and sprouting of preexisting vessels.
Also, HIF1/2𝛼 support vessel maturation by inducing Ang-1, PDGF, and TGF-𝛽 that recruit smooth muscle cells and
pericytes.340
Intratumoral neovessels are often abnormal, immature, and leaky, and expanding tumors are extremely demanding
in terms of nutrients and oxygen. This results in an hypoxic/angiogenic loop generating a tumor tissue that is highly
hypoxic and that contains an excessive/dysfunctional vasculature.341
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4.3 Side effects associatedwith antiangiogenic therapies
Since antiangiogenic compounds are thought to specifically target newly formed, rather than existing vessels or other
normal cell types, no or only minor toxicity was anticipated. However, the expanding use of drugs targeting the VEGF
signaling pathway in cancer unveiled that these antiangiogenic treatments are often associated with a wide spectrum
of toxicities.342,343 Meta-analysesdemonstrateda small risk, around1.5–2.5%of fatal adverseeventswithbothantian-
giogenic TKIs and bevacizumab.
Some adverse effects are shared with conventional chemotherapeutic agents while others are unique and not typ-
ically observed with cytotoxic drugs. Specific toxicities associated with VEGF axis inhibition using VEGF-ligand or
VEGFR inhibitors include cardiovascular effects (hypertension, thromboembolism, left ventricular dysfunction, cere-
brovascular effects) as well as noncardiovascular effects (proteinuria, bleeding/hemorrhage, delayed wound healing,
gastrointestinal perforation, fatigue, and dysphonia).343–346 Other rare class effects of VEGF axis inhibition comprise
reversible posterior leukoencephalopathy (RPLS), osteonecrosis of the jaw (ONJ), and microangiopathic hemolysis.
One study associated bevacizumab with increased risk of death in combination with taxanes or platinum agents but
not in combination with other agents.342
The antiangiogenic TKIs display additional class-related toxicities, including gastrointestinal events (diarrhea,
nausea), thyroid dysfunction, fatigue, stomatitis, myelosuppression, and cutaneous effects.347,348 Some of these
side effects may reflect the promiscuity of kinase inhibitors, which inhibit multiple other receptors in addition to
VEGFRs.
Other drugs like thalidomide, lenalidomide, and pomalidomide, which have both immunomodulatory and antiangio-
genic activity, are associated with thrombotic complications, especially when combined with glucocorticoids and/or
cytotoxic chemotherapy.
4.4 Ways to improve antitumor efficacy of antiangiogenic therapy
4.4.1 Specific targeted therapy versusmultitarget compounds—monotherapy versus combination
therapy
The prototype of specific/targeted therapies is a monoclonal antibody (mAb), which is usually designed against a very
specific target to avoid side effects. Besides bevacizumab,which targetsVEGF, somemAbs exhibit antiangiogenic func-
tions due to crosstalk between the signaling pathways that involve VEGF and other growth factors. This is the case
for anti-EGFR/HER antibodies, such as cetuximab (Erbitux), trastuzumab (Herceptin), and panitumumab (Vectibix).349
Oneof themain drawbacks of this targeted approach is that it often leads to drug resistance, for example, bevacizumab
monotherapy induces a rapid reboost in metastatic patients. A less selective molecule aflibercept (AVE0005, Zaltrap)
functions as a soluble “decoy” VEGF-trap receptor, preventing the binding of VEGF, VEGF-B, and PIGF to the cell sur-
face receptors. Its wider binding spectrum, when compared with bevacizumab, improved progression-free survival,
and overall survival in a clinical trial involvingmetastatic CRC.350
Unlike antibodies and ligand trapmolecules, TKIs (Fig. 3, Table II) cross the cell membrane and interact directly with
the intracellular domain of receptors and/or other signaling molecules. Due to similarities in the kinase domains, most
TKIs offer multitarget activity, good response, and sometimes improved survival rates in phase III clinical trials.351
VEGFR inhibitors, like axitinib, pazopanib, sunitinib, vandetanib, and vatalanib, block also other receptors, such as
PDGFR, c-Kit, EGFR, or RET. Moreover, the VEGFR inhibitor sorafenib targets PDGFR, c-Kit, Flt-3, and BRAF, while
sunitinib inhibits Flt-3 and CSF-1R, and nintedanib (BIBF1120) blocks VEGFR, PDGFR, and FGFR signaling.352 Inter-
estingly, in contrast to agents like bevacizumab and aflibercept that show greater activity when combined with
chemotherapy, TKIs generally display single agent activity.
Nevertheless, TKIs have also been investigated in combination with chemotherapy, especially in advanced NSCLC,
showing clinical benefits in some studies, but failing to prolong overall survival in others.353,354 In general, given the
role of PDGFR, FGFR, and others RTKs in various aspects of tumor biology, especially regarding pericyte and tumor-
cell function, it is difficult to assess the contribution of individual targets to the clinical activity of the multitarget
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F IGURE 3 Chemical structures of FGF and VEGF inhibitors andmultitarget RTKI.
agents.However, preclinical dataprovidedevidence that cotargeting signalingbymultiple proangiogenic factors is nec-
essary to obtain an efficient and durable effect on tumor angiogenesis and growth, implying that multitarget inhibition
might be a promising anticancer strategy. As an example, anti-VEGF therapy combinedwith the endogenous tumstatin
peptide (that binds to 𝛼v𝛽3 integrin) delayed tumor growth in human renal cell carcinoma xenografts onlywhen admin-
istered together.384
Combination therapies with specific or multitargeting antiangiogenics may involve chemotherapy, radiotherapy,
vascular-disrupting agents (VDAs), immunotherapy, or any other new approach. In particular, the use of chemother-
apeutics together with antiangiogenic drugs has been widely explored and is actually a “hot topic” mainly in view of
vascular normalization andmetronomic chemotherapy (better described later herein).
VDAs target the already existing vessels in the tumor environment, thereby provoking a rapid collapse of the
tumor vasculature leading to necrosis at the tumor core (reviewed in385). The clinical success of VDAs depends on
the elimination of the viable tumor rim that is resistant to these compounds. This can be achieved by combinationwith
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F IGURE 4 Features of vascular regression vs normalization. Graphical representation of PROs and CONs of antian-
giogenic strategies that cause blood vessel regression or normalization in tumors. Examples of therapeutic agents are
indicated between brackets.
radio/chemotherapy or antiangiogenic therapy, whichmay abrogate survival of the residual tumor cells and/or neovas-
cularization from the remaining vessels in the tumor rim, respectively. A randomized phase II clinical trial evaluating
the effect of bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma reported encouraging
results in terms of progression-free survival and overall response despite an increased risk of hypertension.386
Tumor angiogenesis also influences immune suppression, and angiogenic factors regulate immune cell traffick-
ing across tumor endothelia.387 For this reason targeting angiogenesis may be an effective approach to increase the
efficacy of different types of immunotherapy, including immune checkpoint blockade.388 Adoptive T-cell transfer in
mice bearing large melanomas in combination with an anti-VEGF antibody significantly augmented antitumor activ-
ity and trafficking of T cells into the tumors.389 The combination of CTLA4 blockade (ipilimumab) with bevacizumab
improved survival of metastatic melanoma patients. This result was associated with endothelial activation and exten-
sive CD8+ and macrophage cell infiltration.390 Several trials in melanoma are ongoing combining bevacizumab and
immunotherapy with anti-PD1 (Nivolumab and MK-3475), anti-PDL1 (Atezolizumab), or anti-CTLA4 (Ipilimumab)
antibodies.390,391 In addition, the combination of anti-Ang-2 (MEDI3617) and anti-CTLA4 (tremelimumab) antibod-
ies, aswell as of pembrolizumab (anti-PD1) and Ziv-Aflibercept are in clinical evaluation for patientswithmelanoma or
advanced solid tumors, respectively.391
These studies will provide the basis for further investigations regarding the interactions among angiogenic factors,
blood vessel formation, immune regulation, andmicroenvironment, eventually paving theway for therapeutic exploita-
tion of new drug combinations.
4.4.2 Concept of vessel normalization versus regression
The tumor vasculature is characterized by increased vessel permeability and high interstitial fluid pressure as a con-
sequence of its tortuous and chaotic structure, scarce pericyte coverage, and discontinuous BM. Instead of vascular
disruption, vessel normalization aims to increase partial oxygen pressure and perivascular cell coverage in the tumor.
This can be obtained through pruning and remodeling of abnormal tumor vessels, leading to vessels resembling normal
tissue vasculature in terms of structure and function (Fig. 4).9
Preclinical studies have shown that anti-VEGF therapy and other antiangiogenic agents can induce vessel
normalization.10,392 In patients, bevacizumab monotherapy was found to induce an increase in pericyte coverage,
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indicative of vascular normalization. Moreover, bevacizumab improved response to chemotherapy, especially in
patients with a high pretreatment MVD, suggesting that this approach is only beneficial in highly vascularized
tumors.393
Many examples of vascular normalization targets are available. Tie2 activation (by Ang-2-binding and Tie2-
activating antibody) reduced tumor growth andmetastasis by inducing tumor vascular normalization, increasing blood
perfusion, and favoring chemotherapeutic drug delivery.394 Dual inhibition of VEGFR/Ang-2 (using cediranib and
MEDI3617) improved survival in orthotopic models of glioblastoma via enhanced vessel normalization and polariza-
tion of TAMs to antitumor phenotypes.395 Pharmacological inhibition of the HGF receptor c-Met normalized vessels
formed in vitro by GBM tumor-derived ECs.396 Preclinical studies suggest that anti-VEGFR2 antibody (DC101) treat-
ment can normalize orthotopic tumor vasculature and enhance the delivery of anticancer agents.397,398
Moreover, inhibition of oncogenic signaling may indirectly trigger vascular normalization. Blocking HER-2 signal-
ing in breast cancer cells with the mAb trastuzumab (Herceptin) normalized breast tumor vessels by modulating
the expression of at least four pro- and antiangiogenic molecules.392 The early antitumor responses of castration in
androgen-dependent carcinomas are primarily vascular effects due to an indirect mechanism where hormone deple-
tion suppresses tumor cell production of angiogenic factors.399 Suppression of BRAF signaling by PLX4720 diminished
the expression of several proangiogenic factors downstream of BRAF, which in turn stabilized vessel architecture,
improved perfusion, and abrogated hypoxia.400 Recently, chloroquine has been shown to induce vascular normaliza-
tion and reducemetastasis by enhancingNotch signaling in ECs.401 Several other studies convincingly reported similar
“normalizing” effects as a consequence of tumor cell oncogene (Ras, PI3K, AKT, EGFR) inhibition.402
These findings are supportive of the vascular normalization hypothesis proposed by Jain61 that tumor blood vessels
can revert from their abnormal phenotype to one more resembling normal tissues through restoration of the balance
between pro- and antiangiogenic factors.
However, it should be taken into account that the benefits of vascular normalization are dose and time
dependent.403 Thus, optimizing combinations of antiangiogenic agents with anticancer treatments will require the
assessment of imaging and/or circulating biomarkers to understand the dynamics of the tumor vascular response and
the balance between vascular normalizing and antivascular effects.
4.4.3 Additional targets and approaches
FGF/FGFR system. Additional angiogenesis regulators are emerging to target in combination with, or in response to,
resistance to anti-VEGF blockade. One of these targets is represented by the FGF/FGFR system, which is activated
in a variety of human tumors, leading to neovascularization, tumor progression, and metastatic dissemination. Efforts
have been made to develop efficacious FGF/FGFR inhibitors for antiangiogenic/antitumor therapies (Fig. 3, Table II).
These include selective andnonselective small-moleculeTKIs, anti-FGFRantibodies, and someextracellular FGF ligand
traps.404,405
Severalwide-spectrum/nonselective TKIs block FGFRswith therapeutic efficacy (see406,407 formore details). Rego-
rafenib is a novel orally active multitarget compound that inhibits a number of proangiogenic RTKs, including FGFR1,
VEGFR2, Tie2, and PDGFR.408 Nintedanib (BIBF1120) interferes with VEGFR, PDGFR, and FGFR pathways.409 All
thesemultitargeting TKIs are endowedwith toxicity profiles often related to their anti-VEGFR action.
Few selective FGFR inhibitors have been characterized and evaluated in clinical trials, like AZD4547 and LY287445
(pan-FGFR inhibitors) and BGJ398 (that targets FGFR1, FGFR2, and FGFR3). These new “FGFR-restricted” drugs
show better tolerability compared to nonselective TKIs. Their most relevant side effects (hyperphosphatemia and tis-
sue calcification) are strictly correlated to the inhibition of the FGF23 pathway. Apart from TKIs, the small-molecule
SSR128129E binds extracellularly to FGFRs and inhibits FGFR signaling by an allosteric mechanism of action, without
affecting orthosteric FGF binding.364
Finally, several FGF traps have been described. FP-1039 is a soluble FGFR1(IIIc)-Fc fusion protein that binds and
inhibits almost all FGFs and has entered clinical trials,362 whereas the long pentraxin-3 (PTX3)-derived small drug
NSC12 represents the first low molecular weight FGF trap.363 Interestingly, at variance with the hyperphosphatemic
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effect of FGFR TKIs, administration of FGF traps (FP-1039 and NSC12) does not affect blood levels of phosphorus,
calcium, and FGF23, and shows a safe profile in murine tumormodels.
Hypoxia. Targeting hypoxic cells and inhibiting the HIF pathway is emerging as an important therapeutic strategy
in cancer biology. Many compounds that target various other signaling pathways act also as indirect HIF inhibitors,
including wortmannin, 2-methoxyestradiol and analogs, geldanamycin and analogs, radicicol and analogs, LYP294002,
CCL-779FK-228, and others.410
Efforts have beenmade to identify directHIF inhibitors. These agents are classified based on their ability to inhibit a
particular step in theHIF pathway, such asHIF protein expression and stability, HIF dimerization, binding of HIF to tar-
getDNA sequences.Many of these small molecules have been evaluated as cancer therapeutics.411 Chetomin disrupts
the HIF-1𝛼/p300 complex and shows antitumor activity in multiple myeloma patient-derived cell lines.412 EZN-2968,
an antagonist of HIF-1𝛼 mRNA impairs the growth of prostate cancer cells.413 PX-12, which mediates HIF-1𝛼 ubiq-
uitination and degradation by increasing spermidine/spermine acetyl transferase (SSAT2), displays antitumor activity
in vitro and in vivo and is being evaluated in Phase II clinical trials.414,415 Digoxin blocks HIF-1𝛼 protein synthesis,
showed promising results in preclinical models of castrate-resistant prostate tumors, and is in clinical trial for prostate
cancer.416,417 Further clinical development of these hypoxia-targeting agentswill require (i) improvement of direct and
indirect methods to measure hypoxia in vivo and to select patients who could benefit from this therapy, as well as (ii)
defining the appropriate treatment schedule.
Vascular targeting. An alternative therapeutic strategy to angiogenesis inhibitors, which block neovascularization,
is represented by “vascular targeting,”418 which relies on mAbs that recognize specific markers on newly formed
blood vessels or in the stroma surrounding these vessels. These Abs selectively deliver potent therapeutic payloads
(such as drugs, cytokines, radionuclides, photosensitizers, and toxins) to disease sites where neoangiogenesis takes
place.419,420
Several antigens have been identified using immunohistochemical, proteomic, or transcriptomic screenings.421,422
Well-known examples are represented by the alternatively spliced extradomains A and B of fibronectin, as well as the
extradomain A1 of tenascin-C. These splice variants are undetectable in normal adult tissues but become strongly
expressed at sites of physiological and tumor angiogenesis.423,424 Anothermarker of angiogenesis, the lipid raft associ-
ated protein bone marrow stromal antigen-2 (Bst-2) appears to be more restricted to hematological malignancies like
lymphomas.425 To date, antibody-drug conjugates (ADC) and immunocytokines are advancing in clinical trials,426 the
latter with promising results, warranting efforts to precisely characterize their mechanisms of action.
Targeting ECmetabolism. Recently, Carmeliet and co-workers postulated the concept that ECmetabolism represents
the engine of ECs, onto which proangiogenic signals (such as VEGF) converge.427 As a consequence, whereas tumors
develop resistance to treatment directed at specific proangiogenic proteins, targeting metabolic pathways may block
the activation of ECs that are exposed to multiple angiogenic mediators (see also Section 3.4). The potential of this
novel approach has recently been illustrated in several elegant studies.
Antiglycolytic therapy with a small molecule blocker of PFKFB3 (3PO) exerted convincing antiangiogenic effects in
different in vitro and in vivomodels. Interestingly, a partial and transient reduction of glycolysis by blockade of PFKFB3
seems to be sufficient to decrease pathological neovascularization.278 Moreover, blockade (or genetic deficiency) of
PFKFB3 results in inhibition of cancer cell invasion andmetastasis. This effect is mainly due to increased tumor vessel
normalization, improved vessel maturation, and perfusion. Indeed, PFKFB3 inhibition lowers the expression of cancer
cell adhesion molecules in ECs, tightens the vascular barrier by reducing VE-cadherin endocytosis, and renders peri-
cytes more quiescent and adhesive.428
In addition, recent findings identified FOXO1 as a major regulator of vascular activation. In particular, the FOXO1-
MYC transcriptional axis emerged as a criticalmetabolic checkpoint for ECproliferation and as a new target for antian-
giogenic therapies.286
Also FA metabolism and nucleotide synthesis might present potential therapeutic antiangiogenic targets. CPT1A
silencing depletes EC stores of aspartate and dNTPs, and pharmacological blockade of CPT1 by etomoxir (an irre-
versible inhibitor ofmitochondrial long-chain FAO) inhibits pathological ocular angiogenesis inmice.289 Thus, targeting
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ECmetabolism represents an emerging therapeutic option as new targets are being identified and/or under character-
ization.
5 CONCLUSION
Almost 50 years of angiogenesis research have resulted in increasingly more complex insights into tumor vascular-
ization. These insights have provided novel hypotheses and concepts that may explain the disappointing anticancer
efficacy of VEGF/VEGFR targeted agents in the clinic, andmay pave theway for improved antiangiogenic cancer treat-
ment.
First, a major part of the complexity in antiangiogenic therapy can be ascribed to the various mechanisms used
by tumors to increase their blood supply (Fig. 1).2 These modes of vascularization may coexist within a tumor,60
but tumors may also shift from one mechanism to another during growth and metastasis, and in response to
treatment.75,309,321 Whereas sprouting angiogenesis has been investigated intensively, the study of these alternative
modes of vascularization faces several problems. Cellular and molecular mediators of these vascularization mecha-
nisms are poorly defined. Intratumoral vessels derived from VM are morphologically indistinguishable from normal
blood vessels. Also,markers that unambiguously distinguish angiogenic versus co-opted vessels are lacking. The extent
towhichEPCs andCSCs contribute to tumor vascularization is unclear in part because of the lack of a consensus defini-
tion of these cell types. Because of these limitations, information is lacking regarding the relative contribution of blood
vessels derived from these different vascularizationmodes in tumors.
A second obstacle to the clinical use of antiangiogenic drugs is the emergence of tumor resistance. Although antian-
giogenic agents were anticipated to target genetically stable cells (i.e., ECs) that lack the capacity to rapidly adapt to
treatment, various tumor escape mechanisms have been observed. Tumors respond to treatment with VEGF/VEGFR-
targeted drugs by the expression and activation of alternative angiogenic factors and pathways.292,294 Moreover,
antiangiogenic treatment has been shown to select for hypoxia-tolerant331 or vessel-independent tumor cells323 or
a tumor vasculature that arises in the absence of angiogenesis.319 Thus, blocking angiogenesis may lead to the occur-
rence of more aggressive tumor cells and increasedmetastasis.
Third, the identification of novel mediators of angiogenesis has further diversified the angiogenesis landscape and
has complicated target selection. Molecular and functional analyses of sprouting angiogenesis have uncovered a link
between neuronal guidance and tip cell sprouting.3,4 Similarly, anti- and proangiogenic functions have been ascribed
to various proteins involved in bone homeostasis.5 Emerging avenues further include the diverse functions elicited by
microRNAs6 and the role of EC metabolism in angiogenesis.7 In particular, the latter is increasingly being recognized
as a key determinant of angiogenesis regulation. Recent in vivo studies showed that a partial and transient reduction
of the glycolytic enzyme PFKFB3 is sufficient to induce endothelial quiescence without affecting glycolysis required
for normal cell maintenance.278 This opens perspectives for the development of novel nontoxic antiangiogenic thera-
pies. However, to date few metabolic enzymes have been studied in ECs. Research has mainly focused on the relation
between a specific metabolic pathway and angiogenesis, and insights into the role of different metabolic pathways in
angiogenesis are lacking. Moreover, the interactions between ECs and the tumormicroenvironment should be consid-
ered. Stromal and tumor cells, but also viruses and bacteria that reside in the tumor microenvironment may compete
with ECs for nutrient and/or metabolite usage.
Themajor question that remains is: how can the recently acquired knowledge be translated to improved anticancer
efficacy of antiangiogenic agents? The answer lies not only in a better understanding of the mechanisms of action and
resistance of currently used anti-VEGF agents, but also in a better selection of the patient population. Antiangiogenic
drugs have predominantly been tested in unselected patients with large tumors. However, since these agents are in
general not cytotoxic, the treatment of small tumors might provide more favorable results. Related to this point, ther-
apywould greatly benefit from the identification of biomarkers that can predict which patients are likely to respond to
a given therapy. Considering the multifactorial nature of neovascularization, which involves a variety of cell types and
mediators, it is unlikely that targeting a single angiogenic factor will afford a protective effect. Future therapies should
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tackle the process at different levels by using multitarget compounds or by blocking EC metabolism, which may over-
rule signals transmitted by various growth factors. Studies should also focus on the elucidation of the genetic basis of
tumor vessel normalization, in order to prevent the selection of more aggressive tumor cell clones and to improve the
delivery and/or activity of radio- and chemotherapy. Thereby, it should be taken into consideration that in the tumor,
not only the blood vessels, but also other components of the tumor microenvironment are abnormal. Thus, therapeu-
tic agents should normalize the entire tumormicroenvironment, including cancer-associated fibroblasts and protumor
immunecells. All together, these future insightsmayboost thedevelopmentof totally newclassesof compoundsand/or
treatment schedules with hopefully improved clinical anticancer efficacy.
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